0001571804false--12-31falseQ320210.0011607900001607900001607900006079000000000000000000000010.1650.1650000015718042021-01-012021-09-3000015718042012-11-062017-08-150001571804gvbt:ChinaMemberus-gaap:ForeignCountryMember2020-01-012020-12-310001571804gvbt:ChinaMemberus-gaap:ForeignCountryMember2021-01-012021-09-300001571804gvbt:HongKongMemberus-gaap:ForeignCountryMember2020-01-012020-12-310001571804gvbt:HongKongMemberus-gaap:ForeignCountryMember2021-01-012021-09-300001571804gvbt:HolmsunCapitalLimitedMember2020-12-310001571804gvbt:HolmsunCapitalLimitedMember2021-09-300001571804gvbt:LeungKwongTakMember2020-01-012020-12-310001571804gvbt:LeungKwongTakMember2021-01-012021-09-300001571804gvbt:MaWaiKinMember2020-01-012020-12-310001571804gvbt:MaWaiKinMember2021-01-012021-09-300001571804gvbt:LamChingWanWilliamMember2020-01-012020-12-310001571804gvbt:LamChingWanWilliamMember2021-01-012021-09-300001571804gvbt:LoKwokLeungMember2020-01-012020-12-310001571804gvbt:LoKwokLeungMember2021-01-012021-09-300001571804gvbt:SupplierMember2020-01-012020-12-310001571804gvbt:SupplierMember2021-01-012021-09-300001571804gvbt:PurchaseEEMember2020-01-012020-12-310001571804gvbt:PurchaseEEMember2021-01-012021-09-300001571804gvbt:PurchaseDDMember2020-01-012020-12-310001571804gvbt:PurchaseDDMember2021-01-012021-09-300001571804gvbt:PurchaseCCMember2020-01-012020-12-310001571804gvbt:PurchaseCCMember2021-01-012021-09-300001571804gvbt:PurchaseBBMember2020-01-012020-12-310001571804gvbt:PurchaseBBMember2021-01-012021-09-300001571804gvbt:PurchaseAAMember2020-01-012020-12-310001571804gvbt:PurchaseAAMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerEMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerEMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerDMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerDMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerCMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerCMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerBMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerBMember2021-01-012021-09-300001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerMember2020-01-012020-12-310001571804us-gaap:CustomerConcentrationRiskMembergvbt:CustomerMember2021-01-012021-09-300001571804us-gaap:ComputerSoftwareIntangibleAssetMember2020-12-310001571804us-gaap:ComputerSoftwareIntangibleAssetMember2021-09-300001571804us-gaap:UseRightsMember2020-12-310001571804us-gaap:UseRightsMember2021-09-300001571804us-gaap:VehiclesMember2020-12-310001571804us-gaap:VehiclesMember2021-09-300001571804us-gaap:OfficeEquipmentMember2020-12-310001571804us-gaap:OfficeEquipmentMember2021-09-300001571804us-gaap:MachineryAndEquipmentMember2020-12-310001571804us-gaap:MachineryAndEquipmentMember2021-09-300001571804us-gaap:BuildingMember2020-12-310001571804us-gaap:BuildingMember2021-09-300001571804us-gaap:VehiclesMember2021-01-012021-09-300001571804us-gaap:OfficeEquipmentMember2021-01-012021-09-300001571804us-gaap:MachineryAndEquipmentMember2021-01-012021-09-300001571804us-gaap:BuildingMember2021-01-012021-09-300001571804gvbt:ChineseRenminbiOneMember2020-01-012020-09-300001571804gvbt:ChineseRenminbiOneMember2020-01-012020-12-310001571804gvbt:ChineseRenminbiOneMember2021-01-012021-09-300001571804gvbt:HongKongToChineseRenminbiMember2020-01-012020-09-300001571804gvbt:HongKongToChineseRenminbiMember2020-01-012020-12-310001571804gvbt:HongKongToChineseRenminbiMember2021-01-012021-09-3000015718042020-01-012020-12-310001571804gvbt:HongKongToUnitedStatesDollarMember2020-01-012020-09-300001571804gvbt:HongKongToUnitedStatesDollarMember2020-01-012020-12-310001571804gvbt:HongKongToUnitedStatesDollarMember2021-01-012021-09-300001571804gvbt:UnitedStatesDollarMember2020-01-012020-09-300001571804gvbt:UnitedStatesDollarMember2020-01-012020-12-310001571804gvbt:UnitedStatesDollarMember2021-01-012021-09-300001571804gvbt:ChineseRenminbiMember2020-01-012020-09-300001571804gvbt:ChineseRenminbiMember2020-01-012020-12-310001571804gvbt:ChineseRenminbiMember2021-01-012021-09-300001571804gvbt:ShanxiGreenBiotechnologyIndustryCompanyLimitedMember2021-09-300001571804gvbt:HongKongProlificMineralResourcesHoldingsLimitedMember2021-09-300001571804gvbt:LightRaiseLimitedMember2021-09-300001571804gvbt:LutuInternationalBiotechnologyLimitedMember2021-09-300001571804gvbt:ShanxiGreenBiotechnologyIndustryCompanyLimitedMember2021-01-012021-09-300001571804gvbt:HongKongProlificMineralResourcesHoldingsLimitedMember2021-01-012021-09-300001571804gvbt:LightRaiseLimitedMember2021-01-012021-09-300001571804gvbt:LutuInternationalBiotechnologyLimitedMember2021-01-012021-09-300001571804gvbt:LutuInternationalMember2017-05-012017-05-120001571804gvbt:ParentsMember2017-05-012017-05-120001571804gvbt:LutuInternationalMember2017-05-120001571804gvbt:ParentsMember2017-05-120001571804gvbt:AbleLeadHoldingsLimitedMember2019-07-300001571804gvbt:BoothUdallFullerPLCMember2017-05-120001571804gvbt:LutuInternationalMembergvbt:MajorityInterestExchangeAgreementMembergvbt:AbleLeadHoldingsLimitedMember2019-07-300001571804gvbt:LutuInternationalMembergvbt:MajorityInterestExchangeAgreementMembergvbt:AbleLeadHoldingsLimitedMember2017-05-012017-05-120001571804gvbt:AbleLeadHoldingsLimitedMember2017-05-012017-05-120001571804gvbt:LutuInternationalMembergvbt:ShareExchangeAgreementMembergvbt:HarcourtCapitalLimitedMember2017-05-012017-05-120001571804gvbt:LutuInternationalMembergvbt:MinorityInterestExchangeAgreementMembergvbt:WoodheadInvestmentsLimitedMember2017-05-012017-05-1200015718042017-05-1200015718042017-05-012017-05-1200015718042016-09-012016-09-300001571804us-gaap:RetainedEarningsMember2021-09-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001571804us-gaap:AdditionalPaidInCapitalMember2021-09-300001571804gvbt:NumberOfCommonSharesOutstandingMember2021-09-300001571804us-gaap:RetainedEarningsMember2021-07-012021-09-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001571804us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001571804gvbt:NumberOfCommonSharesOutstandingMember2021-07-012021-09-3000015718042021-06-300001571804us-gaap:RetainedEarningsMember2021-06-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001571804us-gaap:AdditionalPaidInCapitalMember2021-06-300001571804gvbt:NumberOfCommonSharesOutstandingMember2021-06-3000015718042021-04-012021-06-300001571804us-gaap:RetainedEarningsMember2021-04-012021-06-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001571804us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001571804gvbt:NumberOfCommonSharesOutstandingMember2021-04-012021-06-3000015718042021-03-310001571804us-gaap:RetainedEarningsMember2021-03-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001571804us-gaap:AdditionalPaidInCapitalMember2021-03-310001571804gvbt:NumberOfCommonSharesOutstandingMember2021-03-3100015718042021-01-012021-03-310001571804us-gaap:RetainedEarningsMember2021-01-012021-03-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001571804us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001571804gvbt:NumberOfCommonSharesOutstandingMember2021-01-012021-03-310001571804us-gaap:RetainedEarningsMember2020-12-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001571804us-gaap:AdditionalPaidInCapitalMember2020-12-310001571804gvbt:NumberOfCommonSharesOutstandingMember2020-12-3100015718042020-09-300001571804us-gaap:RetainedEarningsMember2020-09-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001571804us-gaap:AdditionalPaidInCapitalMember2020-09-300001571804gvbt:NumberOfCommonSharesOutstandingMember2020-09-300001571804us-gaap:RetainedEarningsMember2020-07-012020-09-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001571804us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001571804gvbt:NumberOfCommonSharesOutstandingMember2020-07-012020-09-3000015718042020-06-300001571804us-gaap:RetainedEarningsMember2020-06-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001571804us-gaap:AdditionalPaidInCapitalMember2020-06-300001571804gvbt:NumberOfCommonSharesOutstandingMember2020-06-3000015718042020-04-012020-06-300001571804us-gaap:RetainedEarningsMember2020-04-012020-06-300001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001571804us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001571804gvbt:NumberOfCommonSharesOutstandingMember2020-04-012020-06-3000015718042020-03-310001571804us-gaap:RetainedEarningsMember2020-03-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001571804us-gaap:AdditionalPaidInCapitalMember2020-03-310001571804gvbt:NumberOfCommonSharesOutstandingMember2020-03-3100015718042020-01-012020-03-310001571804us-gaap:RetainedEarningsMember2020-01-012020-03-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001571804us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001571804gvbt:NumberOfCommonSharesOutstandingMember2020-01-012020-03-3100015718042019-12-310001571804us-gaap:RetainedEarningsMember2019-12-310001571804us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001571804us-gaap:AdditionalPaidInCapitalMember2019-12-310001571804gvbt:NumberOfCommonSharesOutstandingMember2019-12-3100015718042020-01-012020-09-3000015718042020-07-012020-09-3000015718042021-07-012021-09-3000015718042020-12-3100015718042021-09-3000015718042021-11-10iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureiso4217:HKDiso4217:CNY

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

For the transition period from ___________ to ___________

Commission File No. No. 000-55210

GREEN VISION BIOTECHNOLOGY CORP.
(Exact name of registrant as specified in its charter)

Nevada

7380

98-1060941

(State or Other Jurisdiction

of Incorporation or Organization)

(Primary Standard Industrial

Classification Number)

(IRS Employer

Identification Number)

Rooms 1804-06, 18/F., Wing On House, 71 Des Voeux Road Central,

Hong Kong SAR, China

852-94929967

(Address and telephone of principal executive offices)

Securities registered pursuant to Section 12(b) of the Exchange Act: None.

Securities registered pursuant to Section 12(g) of the Exchange Act:

Common stock, par value $0.001 per share.

(Title of class)

Former address: 1255 W, Rio Salado Parkway, Suite 215, Tempe, Arizona, 85281

(Former name, former address and former fiscal year, if changed since last report)

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years. N/A

Indicate by checkmark whether the issuer has filed all documents and reports required to be filed by Section 12, 13 and 15(d) of the Securities Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

No market value has been computed as of September 30, 2021 based upon the fact that no active trading market has been established.

Applicable Only to Corporate Issuers:

Indicate the number of shares outstanding of each of issuer’s classes of common stock, as of the most practicable date: As of November 10, 2021, there were 160,790,000 shares of Common Stock of the issuer outstanding.

TABLE OF CONTENTS

		Page
PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	3
	Consolidated Balance Sheets as of September 30, 2021 and December 31, 2020	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2021 and 2020	4
	Consolidated Statements of Stockholders’ Deficit and Comprehensive Loss as of September 30, 2021	5
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020	6
	Notes to Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	30
Item 4.	Controls and Procedures	30

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	31
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	34
	Signatures	35

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM: 1 FINANCIAL STATEMENTS

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	Note	September 30, 2021			December 31, 2020
ASSETS		(Unaudited)			(Audited)
Cash and cash equivalents		$	33,253		$	26,734
Accounts receivable, net of allowance for doubtful accounts			-			-
Inventories, net	7		2,699			-
Advance to suppliers			22,643			22,364
Other receivables	4		420			1,822
Total current assets			59,015			50,920

Property, plant and equipment, net	5		2,081,149			2,162,624
Construction in progress			-			-
Intangible assets	6		813,518			822,006
Long term lease prepayment			-			-
Restricted cash			762			820
Total non-current assets			2,895,429			2,985,450
TOTAL ASSETS		$	2,954,444		$	3,036,370

LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable		$	27,612		$	27,272
Advances from customer			16			15
Accrued expenses			249,800			275,832
Accrued payroll			13,357			13,194
Other payables	9		263,340			255,145
Other tax payables			11,904			5,879
Amount due to related parties	11		5,779,162			5,745,866
Amount due to shareholder			4,365,015			4,127,708
Total current liabilities			10,710,206			10,450,911
TOTAL LIABILITIES		$	10,710,206		$	10,450,911

Stockholders’ equity
Common stock, $0.001 par value per share, authorized 750,000,000 and 750,000,000 shares, issued and outstanding 160,790,000 shares at September 30, 2021, and December 31, 2020 respectively			160,790			160,790
Additional paid-in capital			(282,209	)		(282,209	)
Accumulated other comprehensive loss			(145,071	))		(155,163	)
Accumulated deficit			(7,489,272	)		(7,137,959	)
TOTAL STOCKHOLDERS’ DEFICIT			(7,755,762	)		(7,414,541	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT		$	2,954,444		$	3,036,370

See accompanying notes to unaudited consolidated financial statements

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	*Note*	*Three Months Ended* *Sept 30, 2021*		*Three Months Ended* *Sept 30, 2020*		*Nine Months* *Ended* *Sept 30, 2021*		*Nine Months* *Ended* *Sept 30, 2020*
				$				$
Continuing operations		(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Revenue, net			-		9,251		144,689		76,122
Cost of goods sold			-		7,439		73,964		84,472
Gross profit			-		1,812		70,725		(8,350)

Operating expenses
Selling expenses			-		463		58,784		2,263
General and Administrative expenses			117,768		84,054		367,269		258,693
Total operating expenses			117,768		84,517		426,053		260,956

(Loss)/Income from operations			(117,768)		(82,705)		(355,328)		(269,306)

Non-operating income(expense)
Interest income			2		1		9		7
Interest expenses			(1,835)		(1,513)		(3,440)		(3,750)
Other income			10		-		7,467		163,201
Other expense			-		(1,153)		(21)		(29,030)

(Loss)/Income before income taxes			(119,591)		(85,370)		(351,313)		(138,878)
Income taxes	12		-		-		-		-

Net (loss)/income from continuing operations			(119,591)		(85,370)		(351,313)		(138,878)
Net (loss)/income from discontinued operations (Note 15)			-		-		-		(3,565)
Non-controlling interest			-		-		-		-
Net (loss)/income attributable to the Company			(119,591)		(85,370)		(351,313)		(142,443)

Foreign currency translation adjustment			14,819		(44,286)		10,092		(56,849)

Comprehensive (Loss)/Income			(104,772)		(129,656)		(341,221)		(199,292)

Loss per share of common stock	10
Basic and diluted
Continuing operations			(0.074)cents		(0.053)cents		(0.218)cents		(0.086)cents
Discontinued operations			-		-		-		(0.002)cents

Weighted average number of common shares outstanding – basic and diluted			160,790,000		160,790,000		160,790,000		160,790,000

See accompanying notes to unaudited consolidated financial statements

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’DEFICIT AND COMPREHENSIVE INCOME

(UNAUDITED)

	Number of common shares outstanding		Amount		Additional paid-in capital			Accumulated other comprehensive income			Accumulated deficits			Total stockholders’ equity/ (deficit)

Balance, January 1, 2020		160,790,000	$	160,790		(282,209	)		(51,172	)		(6,741,932	)	$	(6,914,523	)
Net loss		-		-		-			-			(23,392	)		(23,392	)
Foreign currency translation adjustment		-		-		-			(9,906	)		-			(9,906	)

Balance, March 31, 2020		160,790,000	$	160,790		(282,209	)		(61,078	)		(6,765,324	)	$	(6,947,821	)
Net loss		-		-		-			-			(33,681	)		(33,681	)
Foreign currency translation adjustment		-		-		-			(2,657	)		-			(2,657	)

Balance, June 30, 2020		160,790,000	$	160,790		(282,209	)		(63,735	)		(6,799,005	)	$	(6,984,159	)
Net loss		-		-		-			-			(85,370	)		(85,370	)
Foreign currency translation adjustment		-		-		-			(44,286	)		-			(44,286	)

Balance, September 30, 2020		160,790,000	$	160,790		(282,209	)		(108,021	)		(6,884,375	)	$	(7,113,815	)

Balance, January 1, 2021		160,790,000	$	160,790		(282,209	)		(155,163	)		(7,137,959	)	$	(7,414,541	)
Net loss		-		-		-			-			(105,933	)		(105,933	)
Foreign currency translation adjustment		-		-		-			1,753			-			1,753

Balance, March 31, 2021		160,790,000	$	160,790		(282,209	)		(153,410	)		(7,243,892	)	$	(7,518,721	)
Net loss		-		-		-			-			(125,789	)		(125,789	)
Foreign currency translation adjustment		-		-		-			(6,480	)		-			(6,480	)

Balance, June 30, 2021		160,790,000	$	160,790		(282,209	)		(159,890	)		(7,369,681	)	$	(7,650,990	)
Net loss		-		-		-			-			(119,591	)		(119,591	)
Foreign currency translation adjustment		-		-		-			14,819			-			14,819

Balance, September 30, 2021		160,790,000	$	160,790		(282,209	)		(145,071	)		(7,489,272	)	$	(7,755,762	)

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	(Unaudited)
	Nine Months Ended September 30,
	2021			2020
Cash flows provided by (used in) continuing operating: activities:
Net loss	$	(351,313	)	$	(138,878	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation		108,017			96,792
Amortization of intangible assets		18,658			17,261
Allowance for doubtful accounts		-			-
Inventory provision reversal		(95,030	)		(87,915	)
Disposal gain of property, plant and equipment		-			(50,953	)
Changes in assets and liabilities:
Accounts receivable		-			10,293
Inventories		92,340			80,558
Advances to suppliers		-			-
Other receivables		1,420			1,900
Restricted cash		69			1,572
Accounts payable		-			-
Advances from customer		-			-
Other payables		4,999			(5,497	)
Other tax payables		5,931			(410	)
Accrued payroll		(2	)		125
Accrued expenses		(25,031	)		(54,326	)
Amount due to related parties		47,836			78,284
Net cash flows provided by (used in) operating activities		(192,106	)		(51,194	)
Cash flows provided by (used in) investing activities:
Proceeds from sale of property, plant and equipment		-			55,653
Net cash flows used for investing activities		-			55,653
Cash flows provided by (used in) financing activities:
Amounts due to shareholder		198,698			(7,612	)
Net cash flows provided by (used in) financing activities		198,698			(7,612	)
Net increase (decrease) in cash from continuing operations:		6,592			(3,153	)

Cash flows provided by (used in) discontinued operating activities:
Net cash provided by (used in) investing activities of discontinued operations		-			(3,565	)
Net cash flows provided by discontinued operations		-			(3,565	)

Net increase (decrease) in cash and cash equivalents		6,592			(6,718	)
Effect of foreign currency translation		(73	)		2,922
Cash – beginning of period		26,734			61,747
Cash – end of period	$	33,253		$	57,951
Supplemental disclosures of cash flow information:
Interest paid	$	1,835		$	3,750
Income taxes	$	-		$	-

See accompanying notes to unaudited consolidated financial statements

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS

Green Vision Biotechnology Corp. (formerly known as Vibe Wireless Corp., originally known as Any Translation Corp.), (the “Company”, “GVBT”), was incorporated under the laws of the State of Nevada on July 5, 2012. The Company was founded to be in the business of translation and interpretation. On November 12, 2015, the Company changed its name from Any Translation Corp. to Vibe Wireless Corp. On September 30, 2016, we changed our name from Vibe Wireless Corp. to Green Vision Biotechnology Corp.

On September 30, 2016, the Company filed a Certificate of Amendment with the Nevada Secretary of State (the “Nevada SOS”) whereby it amended its Articles of Incorporation to increase the Company’s authorized number of shares of common stock from 75 million to 750 million and forward stock split all of its issued and outstanding shares of common stock at a ratio of ten (10) shares for every one (1) share held. The Company’s Board of Directors approved this amendment on September 30, 2016. This stock split has been retroactively applied to the financial statements.

On the same date, September 30, 2016, the Company filed Articles of Merger with the Nevada SOS whereby it entered into a statutory merger with its wholly-owned subsidiary, Green Vision Biotechnology Corp. pursuant to Nevada Revised Statutes 92A.200 et. seq. The effect of such merger is that the Company is the sole surviving entity and changed its name to “Green Vision Biotechnology Corp.”

The investment transaction under the share exchange agreements and contractual agreements as described below (collectively the “Transaction Agreements”) was entered into, between each of the Shareholders of Lutu International Biotechnology Limited (“Lutu International”), a company incorporated under the laws of Cayman Islands and GVBT (the “Investment Transaction”) on May 12, 2017. As a result of closing the Investment Transaction, GVBT acquired part of the shares of Lutu International and assumed management of Lutu International and all its direct and indirect subsidiaries (“the Lutu Group”).

On May 12, 2017, GVBT entered into a share exchange agreement with Harcourt Capital Limited (“Harcourt”), a limited company incorporated in the British Virgin Islands, which holds 6% of the issued and outstanding shares of Lutu International; and Woodhead Investments Limited (“Woodhead”), a limited company incorporated in the British Virgin Islands, which holds 5% of the issued and outstanding shares of Lutu International (the “Minority Interest Exchange Agreement”). Under the Minority Interest Exchange Agreement, Woodhead agreed to transfer GVBT a total of 5% of the issued and outstanding shares of Lutu International. In consideration, GVBT agreed to grant Woodhead, or persons designated by Woodhead, a right to receive a total of 5 million shares of GVBT’s common stock. Under the Minority Interest Exchange Agreement, Harcourt agreed to transfer to GVBT a total of 6% of the issued and outstanding shares of Lutu International. In consideration, GVBT agreed to grant Harcourt, or persons designated by Harcourt, a right to receive a total of 6 million shares of GVBT’s common stock. The transactions under the Minority Interest Exchange Agreement were completed on May 12, 2017.

Able Lead, an 89% shareholder of Lutu International, has an outstanding loan of $4.43 million denominated in Renminbi (“RMB”) owed to an unrelated third party with its maturity date on January 22, 2018 (the “Outstanding Loan”). Able Lead is negotiating an extension of the Outstanding Loan to 2019 with the third-party creditor. Shares of Lutu International held by Able Lead were offered by Able Lead as collateral to secure repayment of the Outstanding Loan (the “Security”).

On May 12, 2017, GVBT entered into a share exchange agreement (the “Majority Interest Exchange Agreement”) with Able Lead, the 89% shareholder of Lutu International. Under the Majority Interest Exchange Agreement, Able Lead agreed to enter into a series of contractual arrangements with GVBT (collectively, the “Contractual Arrangements”) (as described below), in which GVBT assumed management control of the Lutu Group. Able Lead further agreed to deliver the shares of Lutu International to GVBT once the Outstanding Loan is fully repaid. In consideration, GVBT agreed to issue and deliver a total of 89 million shares of GVBT’s common stock to an escrow agent (issued in the name of the escrow agent or its nominee) (the “Escrow Shares “). The Escrow Shares are held in escrow for a period of one year or such period of time to be agreed by GVBT and Able Lead upon the execution of the Majority Interest Exchange Agreement. Conditional upon the full repayment of the Outstanding Loan and the release of the Security, the Escrow Shares shall be released to Able Lead in exchange for the delivery of a total of 89% of the issued and outstanding shares of Lutu International by Able Lead to GVBT. In the event that Able Lead fully repays the Outstanding Loan and causes the release of the Security, then the Escrow Shares shall be delivered to Able Lead. In the event that Able Lead cannot fully repay the Outstanding Loan (within a period of one year, or such period of time to be agreed by GVBT and Able Lead) and cause the release of the Security, then the Escrow Shares shall be delivered to transfer agent for cancellation. Unless otherwise expressly agreed in writing by GVBT and Able Lead, the Majority Interest Exchange Agreement shall be automatically terminated upon the termination of any of the agreements in the Contractual Arrangements described as below. The transactions under the Majority Interest Exchange Agreement were completed on May 12, 2017.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS (continued)

Pursuant to an escrow agreement (the “Escrow Agreement”) entered into between Booth Udall Fuller, PLC (the “Escrow Agent”) and GVBT on May 12, 2017, the Escrow Shares shall be held by Booth Udall Fuller, PLC for a year following the execution of the Majority Interest Exchange Agreement. The Escrow Shares shall not be subject to any lien, attachment, or any other judicial process of any creditor of GVBT, and shall be held and disbursed solely for the purposes and in accordance with the terms of the Majority Interest Exchange Agreement.

On July 30, 2019, the Company cancelled the 89,000,000 shares of common stock, par value $.001 per share, and re-issued them to Able Lead Holdings Limited. The issuance was done pursuant to Section 4(a)(2) of the Securities Act of 1933. as it was a non-public offering. On May 12, 2017, the Company had placed the 89,000,000 shares into escrow with Booth Udall Fuller PLC, pending repayment of a loan and discharge of shares of Lutu International by Able Lead Holdings Limited. Full repayment of such was made on February 27, 2019. Therefore, the 89,000,000 shares were returned from escrow and cancelled. Then they were re-issued to Able Lead Holdings Limited. Thereafter, Able Lead transferred the shares to six (6) shareholders who are not affiliated with GVBT.

On May 12, 2017, GVBT entered into the Contractual Agreements with Lutu International and/or Able Lead. Upon execution of the Contractual Arrangements, GVBT assumed management of Lutu International and its subsidiaries (the “Lutu Group”) and received economic benefits which includes the right to receive the expected residual returns and and/or obligation to absorb expected loss from the Lutu Group. Each agreement in the Contractual Arrangements constitutes valid and binding obligations of the parties of such agreements and is enforceable and valid in accordance with the laws of Cayman Islands. All agreements executed by Lutu International were duly approved by its board of directors and the Shareholders of Lutu International.

Consulting Services Agreement

Pursuant to the exclusive consulting services agreement entered into between GVBT and Lutu International on May 12, 2017, GVBT has the exclusive right to provide to the Lutu Group general business operation services, including advice and strategic planning, as well as consulting services related to the technological research and development of bio-fertilizers. Further, GVBT owns the intellectual property rights developed or discovered through research and development, in the course of providing the consulting services, or derived from the provision of the consulting services. In consideration, Lutu International pays an annual consulting service fees to GVBT in the amount equivalent to all of Lutu International’s net profits for the relevant financial year. The term of this consulting service agreement is five (5) years from its effective date and may be terminated upon GVBT’s written confirmation prior to the expiration of this agreement.

Unless otherwise expressly agreed in writing by GVBT and Able Lead, the Consulting Services Agreement shall be automatically terminated upon the termination of any of the agreements in the Contractual Arrangements or the Majority Interest Exchange Agreement.

Operating Agreement

Pursuant to the operating agreement entered into between GVBT, Lutu International and Able Lead on May 12, 2017, GVBT agreed to provide guidance and instructions on the Lutu Group’s daily operations, financial management and employment issues. Able Lead agreed to designate candidates recommended by GVBT as their representatives on the boards of directors of each member of the Lutu Group. GVBT has the right to appoint senior executives of each member of the Lutu Group. In addition, GVBT agreed to guarantee the Lutu Group’s performance under any agreements or arrangements relating to the Lutu Group’s business arrangements with any third party. In consideration, Lutu International agrees that it will not, and will cause the Lutu Group not to, without the prior consent of GVBT, engage in any transactions that could materially affect their respective assets, liabilities, rights or operations, including but not limited to, incurrence or assumption of any indebtedness, sale or purchase of any assets or rights, incurrence of any encumbrance on any of their assets or intellectual property rights in favor of a third party or transfer of any agreements relating to their business operation to any third party. The term of this operating agreement is five (5) years from its effective date and may be extended and terminated only upon GVBT’s written confirmation prior to the expiration of this agreement.

Unless otherwise expressly agreed in writing by GVBT and Able Lead, the Operating Agreement shall be automatically terminated upon the termination of any of the agreements in the Contractual Arrangements or the Majority Interest Exchange Agreement.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND NATURE OF BUSINESS (continued)

Proxy Agreement

Pursuant to the proxy agreement entered into between Able Lead, Lutu International, and GVBT on May 12, 2017, Able Lead agreed to irrevocably grant a person to be designated by GVBT the right to exercise its voting rights and other rights, including the attendance of, and the voting at the shareholders’ meetings of Lutu International for and on behalf of Able Lead (or the signing of written resolutions in lieu of such meetings) in accordance with applicable laws and its articles of association, including but not limited to the appointment and voting for the directors and chairman of the board as the authorized representative of Able Lead to exercise controlling power in the Lutu Group. The proxy agreement may be terminated by joint consent of the parties or upon 7-day written notice from GVBT. The proxy right granted by the proxy agreement has never been exercised.

Changes Resulting from the Investment Transaction

The closing of the Investment Transaction occurred on May 12, 2017, resulting in a change of control of GVBT. Prior to closing of the Investment Transaction, GVBT had a total of 60,790,000 shares of common stock issued and outstanding. As a result of the closing of the Investment Transaction, GVBT now has a total of 160,790,000 shares of its common stock issued and outstanding, of which 60,790,000 shares, or approximately 37.8%, are owned by the previous existing shareholders of GVBT, with the balance of 100,000,000 shares, or approximately 62.2%, owned by the previous shareholders of Lutu International, with certain shares held in escrow pursuant to the Escrow Agreement.

Following the closing of the Investment Transaction, GVBT began carrying on the business of the Lutu Group. The Lutu Group, with its operation primarily located in the Shanxi Province of China, is engaged in the biotechnology industry, in particular, the production and distribution of bio-fertilizers. Revenues of the Lutu Group are currently generated from China.

Changes to the Board of Directors and Officers

Simultaneous with the closing of the Investment Transaction, there was a change in the officers and directors of GVBT. As authorized by the bylaws, the existing director of GVBT, Mr. Ma Wai Kin, appointed two (2) additional members to the Board of GVBT. Such members are Mr. Lam Ching Wan (also known as William Lam) and Mr. Leung Kwong Tak (also known as Dr. Michael Leung). Mr. Ma also appointed Mr. William Lam as GVBT’s Chief Executive Officer and Mr. Lo Kwok Leung as GVBT’s Chief Financial Officer. Mr. Lo Kwok Leung is not related to Dr. Michael Leung.

All members of the Board shall hold their respective offices for a term of one year from their respective dates of appointment, or until the election and qualification of their successors, and thereafter to resign as a director of GVBT. In accordance with the bylaws, officers are elected by the board of directors and serve at the discretion of the board of directors.

Accounting Treatment

The Investment Transaction was accounted for as a reverse-merger and recapitalization. For financial reporting purposes, Lutu International is the acquirer and GVBT is the acquired company. After completion of the transaction, the assets, liabilities, operations results and cash flow of GVBT that will be reflected in the historical consolidated financial statements prior to the Investment Transaction will be those of Lutu International and its subsidiaries and will be recorded at the historical cost basis of Lutu International and its subsidiaries. Number of shares deemed to be outstanding for the period from January 1, 2018 to the acquisition date will be reflected in the balance of the common stock and paid in capital. The Company changed its fiscal year ended from January 31 to December 31.

Tax Treatment and SEC Filer Status: Small Business Issuer

The Investment Transaction is intended to constitute a reorganization within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the “Code”), or such other tax-free reorganization exemptions that may be available under the Code. Immediately following the Investment Transaction, the filer status of GVBT will be a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K, as promulgated by SEC.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for consolidated financial reporting.

Summary of significant accounting policies

Principles of Consolidation and Presentation

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The historical presentation of the consolidated financial statements includes the financial statements of LUTU INTERNATIONAL BIOTECHNOLOGY LIMITED, and its wholly-owned subsidiaries (collectively referred to herein as the “Company”). All intercompany accounts, transactions, and profits have been eliminated upon consolidation.

The following table depicts the identity of the subsidiaries:

Name of Subsidiary	Place of Incorporation	Attributable Equity Interest %		Registered Capital
Lutu International Biotechnology Limited (RTO accounting acquirer) (1)	Cayman Islands		100	USD100
Light Raise Limited (2)	BVI		100	USD 1
Hong Kong Prolific Mineral Resources Holdings Limited (3)	HKD		100	HKD 2
Shanxi Green Biotechnology Industry Company Limited (4)	PRC		100	RMB 100,000,000

Note:	(1)	Wholly owned subsidiary of Green Vision Biotechnology Corp.
	(2)	Wholly owned subsidiary of Lutu International Biotechnology Limited
	(3)	Wholly owned subsidiary of Light Raise Limited
	(4)	Wholly owned subsidiary of Hong Kong Prolific Mineral Resources Holdings Limited

Use of estimates

America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could materially differ from those estimates.

Significant estimates and judgments inherent in the preparation of these consolidated financial statements include, among other things, accounting for asset impairments, allowances for doubtful accounts, depreciation and amortization, the collection of revenues from the Agricultural Cooperative.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING (continued)

Economic and political risks

The Company’s operations are mainly conducted in the Hong Kong Special Administrative Region (“Hong Kong”) and the People’s Republic of China (“China”) (for the purpose of this Current Report on Form 10-Q, China does not include Hong Kong, Macau Special Administrative Region of the People's Republic of China and Taiwan (The Republic of China) and a large number of customers are located in northern China. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in Hong Kong and China, and by the general state of the economy in Hong Kong and China.

The Company’s operations and customers in Hong Kong and China are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments, and foreign currency exchange. The Company’s results may be adversely affected by changes in the political and social conditions in Hong Kong and China, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion, remittances abroad, and rates and methods of taxation, among other things.

Foreign Currency Translation

The Company’s financial statements are presented in the U.S. dollar ($), which is the Company’s reporting currency, while its functional currency are Chinese Renminbi (RMB) and Hong Kong Dollar (HKD). Transactions in foreign currencies are initially recorded at the functional currency rate ruling at the date of transaction. Any differences between the initially recorded amount and the settlement amount are recorded as a gain or loss on foreign currency transaction in the consolidated statements of income. Monetary assets and liabilities denominated in foreign currency are translated at the functional currency rate of exchange ruling at the balance sheet date. Any differences are taken to profit or loss as a gain or loss on foreign currency translation in the statements of income.

In accordance with ASC 830, Foreign Currency Matters, the Company translated the assets and liabilities into US $ using the rate of exchange prevailing at the applicable balance sheet date and the statements of income and cash flows are translated at an average rate during the reporting period. Adjustments resulting from the translation are recorded in shareholders’ equity as part of accumulated other comprehensive income.

Below is a table with foreign exchange rates used for translation:

For the nine months and year ended, (Average Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Chinese Renminbi (RMB)	RMB		6.47134	RMB		6.89826	RMB		6.99501
United States dollar ($)		$	1.00000		$	1.00000		$	1.00000

As of (Closing Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Chinese Renminbi (RMB)	RMB		6.44795	RMB		6.52825	RMB		6.79194
United States dollar ($)		$	1.00000		$	1.00000		$	1.00000

For the nine months and year ended, (Average Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Hong Kong (HKD)	HKD		7.76690	HKD		7.75599	HKD		7.75747
United States dollar ($)		$	1.00000		$	1.00000		$	1.00000

As of (Closing Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Hong Kong (HKD)	HKD		7.78590	HKD		7.75230	HKD		7.74960
United States dollar ($)		$	1.00000		$	1.00000		$	1.00000
For the nine months and year ended, (Average Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Hong Kong (HKD)	HKD		1.20020	HKD		1.12434	HKD		1.10900
Chinese Renminbi (RMB)		$	1.00000		$	1.00000		$	1.00000

As of (Closing Rate)	Sept 30, 2021			Dec 31, 2020			Sept 30, 2020
Hong Kong (HKD)	HKD		1.20750	HKD		1.18750	HKD		1.14100
Chinese Renminbi (RMB)		$	1.00000		$	1.00000		$	1.00000

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING (continued)

Revenue Recognition

The Company earns revenue by selling merchandise to end using customers primarily through distribution agent and directly to customers.

Revenue is recognized in accordance with the following five steps: when merchandise is purchased by the customer which identifies the contract (step 1) and performance obligations in the contract (step 2) with Customers. When the Company confirmed the price and collectability is reasonably assured which indicates that the transaction price is determined (step 3) and allocated to the performance obligations in the contract (step 4). When the merchandise is delivered to the customer, the performance obligation is satisfied (step 5). Revenue from wholesale distribution agent is recognized after goods delivered, amount fixed or determined and collectability is reasonably assured when the above mentioned five steps are completed.

All revenues are shown net of estimated returns during the relevant period represented by measuring the returns obligations with estimated allowance for sales returns based upon historical experience.

The Company records sales tax collected from its customers on a net basis, and therefore excludes it from revenue as defined in ASC 606, Revenue from Contracts with Customers.

During the nine months ended September 30, 2021 and 2020, the provision of sales return were $Nil respectively.

Cost of Goods Sold

Cost of goods sold includes the cost of materials, labor, and relevant manufacturing expenses.

Selling Expenses

Selling expenses include packaging and shipping costs, as well as advertising and certain expenses associated with operating the Company’s corporate headquarters.

Advertising Costs

The Company expensed all advertising costs as incurred. Advertising expense, net of reimbursement from suppliers, amounted to $Nil and $Nil for the nine months ended September 30, 2021 and 2020 respectively. Advertising expense is included in selling expense and general and administrative expenses in the accompanying consolidated statements of income.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. Summary of significant accounting policies (continued)

Leases

On January 1, 2019, the Company adopted Topic 842 using the modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts have not been adjusted and continue to be reported in accordance with its historical accounting under Topic 840.

The Company elected the package of practical expedients permitted under the transition guidance, which allowed it to carry forward its historical lease classification, its assessment on whether a contract was or contains a lease, and its initial direct costs for any leases that existed prior to January 1, 2019. The Company also elected to combine its lease and non-lease components and to keep leases with an initial term of 12 months or less off the balance sheet and recognize the associated lease payments in the consolidated statements of income on a straight-line basis over the lease term.

Upon adoption, the Company recognized ROU assets with corresponding liabilities on the consolidated balance sheets. The ROU assets include adjustments for prepayments and accrued lease payments. The adoption did not impact its beginning retained earnings, or its prior year consolidated statements of income and statements of cash flows.

Under Topic 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of its leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that it will exercise such options.

Operating leases are included in operating lease right-of-use assets, operating lease liabilities, current and non-current operating lease liabilities, on the consolidated balance sheets.

The Company did not have a lease that met the criteria of a capital lease. Leases that do not qualify as a capital lease are classified as an operating lease. Operating lease rental expenses included in selling, general and administrative expenses for the nine months ended September 30, 2021 and 2020 were $Nil and $Nil respectively.

Accounts Receivable

Accounts receivable is recognized and carried at the original invoice amount less allowance for any uncollectible amounts. An allowance for doubtful accounts is maintained for all customers based on a variety of factors, including the industry practice, the length of time the receivables are past due, significant one-time events and historical experience. The Company is selling products delivered to certain customers which are closed to Agriculture Cooperatives as defined by ASC 905 “Agriculture”. The collection cycle may be varied and depended on the growing crops cycle.

Management reviews and adjusts this allowance periodically based on historical experience and its evaluation of the collectability of outstanding accounts receivable. The Company evaluates the credit risk of its customers utilizing historical data and estimates of future performance. Bad debts are written off as incurred.

Outstanding accounts balances are reviewed individually for collectability. The Company does not charge any interest income on trade receivables. Accounts balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, the Company has not charged off any balances as it has yet to exhaust all means of collection.

During the nine months ended September 30, 2021 and year ended December 31, 2020, the provision of doubtful debts were $Nil and $Nil respectively.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. Summary of significant accounting policies (continued)

Inventories

Inventories primarily consist of merchandise inventories and are stated at lower of cost or market and net realizable value. Cost of inventories is calculated on the weighted average basis which approximates cost.

Management regularly reviews inventories and records valuation reserves for damaged and defective returns, inventories with slow-moving or obsolescence exposure and inventories with carrying value that exceeds market value. Because of its product mix, the Company has not historically experienced significant occurrences of obsolescence.

Inventory shrinkage is accrued as a percentage of revenues based on historical inventory shrinkage trends. The Company performs physical inventory count of its stores once per quarter and cycle counts inventories at its distribution centers once per quarter throughout the year. The reserve for inventory shrinkage represents an estimate for inventory shrinkage for each store since the last physical inventory date through the reporting date.

These reserves are estimates, which could vary significantly, either favorably or unfavorably, from actual results if future economic conditions, consumer demand and competitive environments differ from expectations.

During the nine months ended September 30, 2021 and year ended December 31, 2020, the provision of inventory reversal were $95,030 and $89,148 respectively.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost. Significant additions or improvements extending useful lives of assets are capitalized. Maintenance and repairs are charged to expense as incurred. Depreciation is provided over the estimated useful lives, using the straight-line method with 5% scrape value as follows:

Buildings		20 years
Machinery & equipment		10 years
Office equipment		3 years
Motor vehicles		4 years

Land Use Rights

According to the laws of the PRC, the government owns all the land in the PRC. Companies or individuals are authorized to possess and use the land only through the land use rights granted by the government. The land use rights represent cost of the rights to use the land in respect of properties located in the PRC. Land use rights are carried at cost and amortized on a straight-line basis over the period of rights of 50 years.

Goodwill

Goodwill represents the excess of purchase price over fair value of net assets acquired. Under ASC 350, Intangibles — Goodwill and Other, goodwill is not amortized but evaluated for impairment annually or whenever events or changes in circumstances indicate that the value may not be recoverable.

The Company performed an annual impairment test as of the fiscal year ended December 31, 2020, and a quarter review as of the period ended September 30, 2021, and determined that the impairment loss in the amount of $Nil and $Nil were recorded respectively.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. Summary of significant accounting policies (continued)

Long-lived Assets

The Company reviews long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

Long-lived assets are reviewed for recoverability at the lowest level in which there are identifiable cash flows, usually at the store level. The carrying amount of a long-lived asset is not considered recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use of the asset. If the asset is determined not to be recoverable, then it is considered to be impaired and the impairment to be recognized is the amount by which the carrying amount of the asset exceeds the fair value of the asset, determined using discounted cash flow valuation techniques, as defined in ASC 360, Property, Plant, and Equipment.

The Company determined the sum of the undiscounted cash flows expected to result from the use of the asset by projecting future revenue and operating expense for each store under consideration for impairment. The estimates of future cash flows involve management judgment and are based upon assumptions about expected future operating performance. The actual cash flows could differ from management’s estimates due to changes in business conditions, operating performance and economic conditions.

During the reporting periods, the Company performed the evaluation and there was no impairment loss.

Cash and Concentration of Credit Risk

The Company maintains cash in bank deposit accounts in Hong Kong and PRC, and considers all highly liquid investments purchased with original maturities of nine months or less to be cash equivalents. The Company performs ongoing evaluations of the institution to limit its concentration risk exposure.

The Company’s customers are mainly located in the northeastern China. Because of this, the Company is subject to regional risks, such as the economy, regional financial conditions and unemployment, weather conditions, power outages, and other natural disasters specific to the region in which the Company operates.

Retirement Benefit Plans

Full time employees of the Company in China participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require the Company to make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company accounts the mandated defined contribution plan under the vested benefit obligations approach based on the guidance of ASC 715, Compensation—Retirement Benefits.

The total amounts for such employee benefits which were expensed were $3,225 and $821 for the nine months ended September 30, 2021 and 2020 respectively.

Income Taxes

The Company accounts for income tax using an asset and liability approach and allows for recognition of deferred tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future realization is uncertain.

Segment Reporting

The Company operates in one industry segment, operating manufacturing and selling of organic bio-fertilizer. ASC 280, Segment Reporting, establishes standards for reporting information about operating segments. Given the economic characteristics of the similar nature of the products sold, the type of customer and the method of distribution, the Company operates as one reportable segment as defined by ASC 280, Segment Reporting.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 2. Summary of significant accounting policies (continued)

Basic and diluted earnings (loss) per share

In accordance with ASC No. 260 “Earnings Per Share”, the basic earnings (loss) per common share is computed by dividing net earnings (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted earnings (loss) per common share is computed similarly to basic earnings (loss) per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

Recently Issued Accounting Guidance

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments (ASU 2016-13). The main objective of the standard is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In issuing this standard, the FASB is responding to criticism that today’s guidance delays recognition of credit losses. The standard will replace today’s “incurred loss” approach with an “expected loss” model. The new model, referred to as the current expected credit loss (“CECL”) model, will apply to: (1) financial assets subject to credit losses and measured at amortized cost, and (2) certain off-balance sheet credit exposures. The standard is applicable to loans, accounts receivable, trade receivables, and other financial assets measured at amortized cost, loan commitments and certain other off-balance sheet credit exposures, debt securities (including those held-to-maturity) and other financial assets measured at fair value through other comprehensive income, and beneficial interests in securitized financial assets. The CECL model does not apply to available-for-sale debt securities. For available-for-sale debt securities with unrealized losses, entities will measure credit losses in a manner similar to what they do today, except that the credit losses will be recognized as allowances rather than reductions in the amortized cost of the securities. Accordingly, the new methodology will be utilized when assessing the Company’s financial instruments for impairment. As a result, entities will recognize improvements to estimated credit losses immediately in earnings rather than as interest income over time, as they do today. The ASU also simplifies the accounting model for purchased credit-impaired debt securities and loans. ASU 2016-13 also expands the disclosure requirements regarding an entity’s assumptions, models, and methods for estimating the allowance for loan and lease losses. ASU 2016-13 is effective for years beginning after December 15, 2019, including interim periods within those fiscal years under a modified retrospective approach. Early adoption is permitted for the periods beginning after December 15, 2018. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement (ASU 2018-13), which modifies the disclosure requirements on fair value measurements, including removing the requirement to disclose (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, (2) the policy for timing of transfers between levels and (3) the valuation processes for Level 3 fair value measurements. ASU 2018-13 also added new disclosures including the requirement to disclose (a) the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and (b) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2019 and early adoption is permitted. This standard will only impact the disclosures pertaining to fair value measurements. The Company adopted the guidance from July 1, 2020. The Company finalized its analysis and the adoption of this guidance has no material impact on the Company’s consolidated financial statements and its internal controls over financial reporting.

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. The Company does not expect that the requirements of ASU 2019-12 will have a material impact on its consolidated financial statements.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3. GOING CONCERN

As of September 30, 2021 and December 31, 2020, the Company has an accumulated deficit of $7,489,272 and $7,137,959 respectively, and its current liabilities exceed its current assets resulting in negative working capital of $10,651,191 and $10,399,991 respectively. In view of the matters described above, recoverability of a major portion of the recorded asset amounts and realization of the portion of current liabilities into revenue shown in the accompanying balance sheets are dependent upon continued operations of the Company, which in turn are dependent upon the Company’s ability to raise additional financing and to succeed in its future operations. The Company may need additional cash resources to operate during the upcoming 12 months, and the continuation of the Company may be dependent upon the continuing financial support of investors and/or stockholders of the Company. However, there is no assurance that equity or debt offerings will be successful in raising sufficient funds to assure the eventual profitability of the Company. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Management has taken the following steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is actively pursuing (i) additional funding which would enhance capital employed; and (ii) strategic partners which would increase revenue bases or reduce operation expenses. Management believes that the above actions will allow the Company to continue its operations throughout this fiscal year.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4. OTHER RECEIVABLES

Other receivables consisted of the following:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Deposits	$	108,145		$	106,815
Prepaid expenses		1,085			2,479
Advance to employee		12,788			12,631

Less: Allowance for doubtful debts		(121,598	)		(120,103	)

Total	$	420		$	1,822

NOTE 5. PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment consisted of the following:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Buildings	$	3,065,902		$	3,028,189
Machinery & equipment		-			-
Office equipment		65,832			65,041
Motor vehicles		70,828			69,956

Total property, plant and equipment		3,202,562			3,163,186
Less: accumulated depreciation and impairment charges		(1,121,413	)		(1,000,562	)

Total property, plant and equipment, net	$	2,081,149		$	2,162,624

The depreciation expenses for the nine months ended September 30, 2021 and 2020 were $108,017 and $96,792 respectively.

The depreciation expenses for the three months ended September 30, 2021 and 2020 were $35,996 and $34,096 respectively.

NOTE 6. INTANGIBLE ASSETS

Intangible assets consisted of the following:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Land use rights	$	1,248,365		$	1,233,010
Software system		1,362			1,344
Less – accumulated amortization		(436,209	)		(412,348	)

Total intangible assets, net	$	813,518		$	822,006

The amortization expenses of land use rights and software systems for the nine months ended September 30, 2021 and 2020 were $18,658 and $17,261 respectively.

The amortization expenses of land use rights and software systems for the three months ended September 30, 2021 and 2020 were $6,220 and $5,832 respectively.

Future amortization of land use rights and software systems is as follows:

Years ending December 31,	Amount
2021	$	6,219
2022		24,877
2023		24,877
2024		24,877
2025		24,877
Thereafter		707,791

Total	$	813,518

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7. INVENTORIES

Inventories consisted of the following:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Raw material	$	48,251		$	47,657
Finished goods		1,677			-
Goods on consignment		23,351			23,528
Less: Provision of inventory		(70,580	)		(71,185	)

Inventories, net	$	2,699		$	-

NOTE 8. CONCENTRATIONS OF CREDIT RISK AND MAJOR CUSTOMERS

Sales:

Customer	As at Sept 30, 2021					As at December 31, 2020
A	$	112,054		77	%	$	29,743	34	%
B		25,849		18	%		18,555	21	%
C		6,786		5	%		9,278	11	%
D		-	-		%		7,944	9	%
E		-	-		%		5,219	6	%
Total	$	144,689		100	%	$	70,739	81	%

Purchases:

Supplier	As at Sept 30, 2021					As at December 31, 2020
AA	$	71,891		99	%	$	37,302		100	%
BB		1,018		1	%		-	-		%
CC		-	-		%		-	-		%
DD		-	-		%		-	-		%
EE		-	-		%		-	-		%
Total	$	72,909		100	%	$	37,302		100	%

NOTE 9. OTHER PAYABLES

Other payables consisted of the following:

	Sept 30, 2021		December 31, 2020
	(unaudited)		(audited)
Amount due to third parties		248,139		245,088
Payables to employees		1,984		1,960
Miscellaneous	$	13,217	$	8,097

Total other payables	$	263,340	$	255,145

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 10. LOSS PER SHARE

The Company calculates earnings per share in accordance with ASC 260, Earnings Per Share, which requires a dual presentation of basic and diluted earnings per share. Basic earnings per share are computed using the weighted average number of shares outstanding during the fiscal year. Potentially dilutive common shares consist of convertible preferred stock (using the if-converted method) and exercisable warrants and stock options outstanding (using the treasury method). The following table sets forth the computation of basic and diluted net income per common share:

The following table sets forth the computation of basic and diluted net income per common share:

Period ended September 30,	Sept 30, 2021 (unaudited)			Sept 30, 2020 (unaudited)

Net loss attributable to ordinary shareholders for computing basic net loss per ordinary share
-Continuing	$	(351,313	)	$	(138,878	)
-Discontinued	$	-		$	(3,565	)
Weighted-average shares of common stock outstanding in computing net loss per common stock
Basic		160,790,000			160,790,000
Diluted		160,790,000			160,790,000
Basic and Diluted loss per share of common stock-
-Continuing		(0.218	)cents		(0.086	)cents
-Discontinued		-			(0.002	)cents

NOTE 11. AMOUNT DUE FROM / TO RELATED PARTIES

Key management compensation

The Company incurred the following compensation with key management personnel, which are defined by ASC 850, Related Party Disclosures, as those persons having authority and responsibility for planning, directing and controlling the activities of the Company, including directors and management.

	Sept 30, 2021 (unaudited)		Dec 31, 2020 (audited)

Salaries and wages - Lo Kwok Leung	$	6,688	$	21,661
Director fees - Lam Ching Wan, William		34,765		46,416
Director fees - Ma Wai Kin		23,177		30,944
Director fees - Leung Kwong Tak		24,336		18,965

Total salaries and director fees	$	88,966	$	117,986

Related party transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. Balances and transactions between the Company and its subsidiary have been eliminated on consolidation and are not disclosed in this note.

Related party balances included in the statement of financial position are all non-interest bearing, unsecured and due on demand.

The details for amount due to related parties were as follows:

Amount as at	Sept 30, 2021		December 31,2020
	(unaudited)		(audited)
Holmsun Capital Limited (a) (b)		5,779,162		5,745,866
	$	5,779,162	$	5,745,866

(a)	Common director, LEUNG Kwong Tak of operating subsidiary Lutu International Biotechnology Limited
(b)	Common shareholder, LEUNG Kwong Tak of operating subsidiary Lutu International Biotechnology Limited

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12. INCOME TAXES

The Company and its subsidiaries have no operation in United States, Cayman Islands and British Virgin Islands, and are not subject to any domestic income tax. Therefore, no domestic income tax of United States, Cayman Islands and British Virgin Islands are paid in the quarter ended September 30, 2021 and year ended December 31, 2020.

Hong Kong Prolific Mineral Resources Holdings Limited was incorporated in Hong Kong and is subjected to Hong Kong profits tax rate of 16.5% for the nine months ended September 30, 2021 and 2020. Income tax (reversal) expense amounted to $Nil for the quarter ended September 30, 2021 and year ended December 31, 2020.

A reconciliation of the provision for income taxes with amounts determined by applying the Hong Kong profit rate of 16.5% to income before income taxes is as follows:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Profit (Loss) before income tax	$	(169,807	)	$	(270,342	)
Temporary Difference		-			-
Permanent Difference		-			-
Taxable loss	$	(169,807	)	$	(270,342	)
Hong Kong Profits Tax rate		16.5	%	16.5%%
Current tax credit	$	28,018		$	44,606
Less: Valuation allowance		(28,018	)		(44,606	)
	$	-		$	-

No deferred tax has been provided as there are no material temporary differences arising during the quarter ended September 30, 2021 and year ended December 31, 2020.

Shanxi Green Biotechnology Industry Company Limited was incorporated in the PRC and are subjected to income taxes under the current laws of the PRC. The EIT rate of PRC was 25% for the quarter ended September 30, 2021 and year ended December 31, 2020.

Profit (loss) before income tax of $ (181,459) and $(125,782 for the quarter ended September 30, 2021 and year ended December 31, 2020 respectively, were attributed to operations in China. The income tax expenses consisted of the following:

	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Profit (Loss) before income tax	$	(181,459	)	$	(125,782	)
Temporary Difference		-			-
Permanent Difference		-			-
Taxable profit (loss)	$	(181,459	)	$	(125,782	)
China Enterprise Income Tax rate		25	%		25.0	%
Current tax credit(debit)	$	45,365		$	31,446
Less: Valuation allowance		(45,365	)		(31,446	)
	$	-		$	-

No deferred tax has been provided as there are no material temporary differences arising during the quarter ended September 30, 2021 and year ended December 31, 2020.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 13. SEGMENT INFORMATION

FASB Accounting Standard Codification Topic 280 (ASC 280) “Segment Reporting” establishes standards for reporting information about operating segments in financial statements. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance.

In the quarter ended September 30, 2021 and year ended December 31, 2020, the Company is regarded as a single operating segment, being engaged in the manufacturing of bio-fertilizer. This principal activity and geographical market are substantially based in China, accordingly, no operating or geographical segment information are presented.

NOTE 14. COMPREHENSIVE INCOME

Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the consolidated statements of income and are recorded directly into a separate section of shareholders’ equity on the consolidated balance sheets. Comprehensive income and its components consist of the following:

Period and Year Ended	Sept 30, 2021			December 31, 2020
	(unaudited)			(audited)
Net loss	$	(351,313	)	$	(396,027	)
Other comprehensive income, net of tax
Foreign currency translation adjustment		10,092			(103,991	)

Comprehensive loss	$	(341,221	)	$	(500,018	)

NOTE 15. discontinued operations

On September 26, 2019, the Company has resolved to discontinue the operation of the subsidiary company, Shenzhen Qianhai Lutu Supply Chain Management Company Limited. On September 26, 2019 and onwards, any operation from Shenzhen Qianhai Lutu Supply Chain Management Company Limited has been classified as discontinued operations on the statement of operations. Previous period’s operation has been similarly classified for comparative purposes. A breakdown of discontinued operation for the nine months ending September 30, 2021 and 2020 is as follows:

Nine Months Ended September 30	2021			2020

Operating expenses	$			$
Selling expenses		-			-
General and administrative expenses		-			-
Loss from operations		-	-		-
Non-operating income (expense)					-
Interest income		-			-
Interest expense		-			-
Other income		-			-
Other expense		-			-
Loss on deregister of subsidiary		-			(3,565	)
Loss before income taxes		-			(3,565	)
Income tax		-			-
Net loss	$	-		$	(3,565	)

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 16. LEGAL PROCEEDINGS

Civil case with Mr. Yao Gui Mu

Yao Gui Mu (“the Plaintiff”), former operation manager of the subsidiary in Shanxi, Shanxi Green Biotechnology Industry Company Limited (“the Shanxi Subsidiary”), brought a lawsuit against the Shanxi Subsidiary, in the District People’s Court of Jin Zhong City, Yu Ci District. The subject dispute of the lawsuit concerns an unsettled current account balance of $141,550 (RMB900,000) which was claimed to be a loan advanced to the Company by the Plaintiff. Together with the subject dispute, the Plaintiff also claimed the relevant interest was RMB513,100 calculated from November 6, 2012 to August 15, 2017 with 1% monthly interest rate. The Company’s PRC lawyer had submitted a Statement of Defense on November 23, 2017 to The District People’s Court of Yuci District, Jin Zhong City (“the Court”). A court hearing was held on December 5, 2017. Upon the request by the Court, Shanxi Subsidiary provided supplemental evidence to the Court on 16 January 2018. The second hearing was held on September 19, 2018.

The District People’s Court of Jin Zhong City, Yu Ci District released the civil judgement decision (2017) 晋0702 民初3879号, that there were not sufficient evidence provided by the Plaintiff for the dispute, and the Court did not support for the claim of loan and related interest against the Shanxi Subsidiary. The judgement decision dated on August 31, 2018.

Yao Gui Mu (“the Appealer”) appeal for the decision to the Intermediate People’s Court of Shanxi Province, Jin Zhong City. On May 10, 2019, the Intermediate People’s Court of Shanxi Province, Jin Zhong City released civil judgement decision (2019) 晋07民終355号, that due to the fact that there was a second hearing held on September 19, 2018 after the judgement decision made on August 31, 2018, which was a severe disorder of procedures. Therefore, the civil judgement decision (2017) 晋0702 民初3879号 was revoked and the case was put to re-trial, which was subsequently carried out on October 16, 2019.

On December 16, 2019, the Court released the civil judgement decision (2019) 晋0702 民初3543号之一, that the related dispute loan was being a criminal case under police investigation. Before the police formed a decision, the Court could not confirm that the civil case was under the district court’s judgement jurisdiction. Therefore, the lawsuit against the Shanxi Subsidiary was rejected.

Yao Gui Mu (“the Appealer”) appeal for the decision (2019) 晋0702 民初3543号之一to the Intermediate People’s Court of Shanxi Province, Jin Zhong City. On June 29, 2020, the Intermediate People’s Court of Shanxi Province, Jin Zhong City released civil judgement decision (2020) 晋07民終1734号, agreed with the original civil judgement and reject the appeal.

On May 20, 2021, Yao Gui Mu (“the Plaintiff”) once again re-brought the lawsuit against the Shanxi Subsidiary to the District People’s Court of Jin Zhong City, Yu Ci District, after the police formed the decision on April 16, 2021, that no prosecution against the Plaintiff. On July 26, 2021, a court hearing was held and the trail completed. The judgement decision will be released not later than end of this year.

For the relevant interest of RMB513,100 claimed by the Plaintiff, according to the company’s lawyer, there is no evidence showing that it is more likely than not that the Company will be liable for the said interest. Hence, no provision was made as at September 30, 2021.

Table of Contents

GREEN VISION BIOTECHNOLOGY CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 16. LEGAL PROCEEDINGS (CONTINUED)

Criminal investigation regarding a potential fraud with one of its former customers

Management of the Company suspects that there was a potential fraud committed in the sales made to one of its previous customers. Management reported to the local police of Yuci District, Jinzhong City, Shanxi Province, China about the said potential fraud. The Bureau of Public Security of Yuci District officially undertook the case and initiated investigation procedures on 11 September 2017. Management has been informed that the case is currently under criminal investigation by relevant authorities.

On May 6, 2021, the Management has been informed by the police authorities about no case for investigation decision晋中榆公不立字(2021) 000030号, because there was no sufficient evidence for the trial and no criminal prosecution will carry out.

The Company disagreed with the decision and appeal to the People’s Procuratorate of Jin Zhong City, Yu Ci District on May 7, 2021, and the appeal was accepted on May 21, 2021. On August 11, 2021, the People's Procuratorate of Jun Zhong City, Yu Ci District made the decision 榆检二部移字[2021]Z4号to send back the case to the Bureau of Public Security of Jun Zhong City, Yu Ci District to reconsider the procedure for prosecution according to the regulation applied.

Criminal investigation against one of GVBT’s former employee

Management of the Company suspects that one of its former senior staff may have committed the offence of “unlawfully taking possession of company property through taking advantage of his position” under his employment with the Company. Management reported to the local police of Yuci District, Jinzhong City, Shanxi Province, China about the said potential fraud on 10 October, 2017. The Bureau of Public Security of Yuci District officially undertook its case and initiated investigation procedures on 28 January 2018. Management has been informed that the case is currently under criminal investigation by relevant authorities in China.

On April 16, 2021, the Management has been informed by the police authorities about no case for investigation decision晋中榆公不立字(2021) 000018号, because there was no sufficient evidence for the trial and no criminal prosecution will carry out.

The Company disagreed with the decision and appeal to the People’s Procuratorate of Jin Zhong City, Yu Ci District on May 7, 2021, and the appeal was accepted on July 5, 2021.

Besides the disclosure stated above, management is not aware of any other legal proceedings contemplated by any governmental authority or any other party involving us or our properties. As of the date of this Quarterly Report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. Management is not aware of any other legal proceedings pending or that have been threatened against us or our properties.

NOTE 17. SUBSEQUENT EVENT

COVID-19

COVID-19 continues to spread rapidly to many parts of China and other parts of the world. The pandemic has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in China and elsewhere. In accordance with recommended and mandated restrictions by relevant government and public health officials in light of the COVID-19 outbreak, the Company’s operations had been slightly affected by the COVID-19. As of the issuance date of this report, the extent to which the COVID-19 impacts the Company’s results will depend on future developments, which are uncertain and cannot be predicted, including new information which may emerge concerning the severity of the COVID-19 and the actions to contain the COVID-19 or treat its impact, among others.

Management has evaluated all activities and concluded that there were no other subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements except for the disclosures in Note 16 and the mentioned above matters.

All subsequent events are being disclosed in the Company’s periodic reports that are currently in preparation for filing. Such events shall be described in detail therein.

Table of Contents

FORWARD LOOKING STATEMENTS

Statements made in this Form 10-Q that are not historical or current facts are "forward-looking statements". These statements often can be identified by the use of terms such as "may," "will," "expect," "believe," "anticipate," "estimate," "approximate" or "continue," or the negative thereof. We intend that such forward-looking statements be subject to the safe harbors for such statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward-looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

GENERAL

Green Vision Biotechnology Corp. (the “Company”), formerly known as Vibe Wireless Corp., also formerly known as Any Translation Corp., was incorporated under the laws of the State of Nevada on July 5, 2012. We were founded to be in the business of translation and interpretation. The Company undertook translation and interpretation projects for various fields from business, economics, to science issues. The Company later adopted a business plan to pursue business opportunities in the global telecommunications industry.

On September 2, 2015, a change in control of the Company took place by virtue of the Company's largest shareholder and sole officer and director at that time, selling 4,000,000 shares of the Company's common stock to Forestbay Capital Partners II, LLC, a Delaware limited liability company. Such shares represented 65.8% of the Company's total issued and outstanding shares of common stock. As part of the sale of the shares, Forestbay Capital Partners arranged with the former officer and director, prior to his resignation as the sole officer and director of the Company Board, to appoint Mr. Edward Mooney as the sole officer and director of the Company. Mr. Mooney is the Manager of Forestbay Capital Partners II, LLC.

On November 12, 2015, we changed our name to Vibe Wireless Corp in connection with merging with our wholly-owned subsidiary. This name change and our ticker symbol change was acknowledged by FINRA and effected in the market on November 23, 2015.

The Company was originally incorporated under the laws of the State of Nevada on July 5, 2012 as Any Translation Corp.

On September 30, 2016, the Company filed a Certificate of Amendment with the Nevada Secretary of State (the “Nevada SOS”) whereby it amended its Articles of Incorporation to increase the Company’s authorized number of shares of common stock from 75 million to 750 million and forward split all of its issued and outstanding shares of common stock at a ratio of ten (10) shares for every one (1) share held. The Company’s Board of Directors approved this amendment on September 30, 2016. This stock split has been retroactively applied to the financial statements.

On September 30, 2016, the Company filed Articles of Merger with the Nevada SOS whereby it entered into a statutory merger with its wholly-owned subsidiary, Green Vision Biotechnology Corp. pursuant to Nevada Revised Statutes 92A.200 et. seq. The effect of such merger is that the Company is the surviving entity and changed its name to “Green Vision Biotechnology Corp.”

On September 30, 2016, the Company filed an Issuer Company-Related Action Notification Form with FINRA requesting that the aforementioned forward split and name change be effected in the market. The Company also requested that its ticker symbol be changed to “GVBT”. This name change and our ticker symbol change was acknowledged by FINRA and effected in the market on November 27, 2016.

As disclosed in our Current Report on Form 8-K dated May 12, 2017 there was a change in our management. Effective May 3, 2017, the Company accepted the resignation of Edward P. Mooney as the sole officer of the Company and as the sole member of the Company’s board of directors. Simultaneously, Mr. Ma Wai Kin, was elected as the Company’s President, Secretary, Treasurer and a member of the Board of Directors.

Table of Contents

Results of Operations

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue our operation.

We expect we will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through, among other things, the sale of equity or debt securities.

Result of Operations for the Three months ended September 30, 2021 and 2020

Revenue was $Nil for the three months ended September 30, 2021 (“Q3”), decreased by $9,251, or 100% from $9,251 for the three months ended September 30, 2020 (“Comparable Quarter”). The decrease in revenue during the Q3 as compared to the Comparable Quarter was due to the significant decrease in activities resulted of the outbreak of COVID-19. Most of the commercial activities had been shut down.

Cost of sales was decreased by $7,439, or 100% from $7,439 in the Comparable Quarter to $Nil in Q3. The decrease was corresponding with the decrease in the sales revenue.

Gross profit was decreased by $1,812, or 100% from $1,812 in the Comparable Quarter to $Nil in Q3. In terms of percentage of revenue, the gross profit percentage was decreased to 0% for Q3 as compared to 19.6% for the Comparable Quarter. The decrease of gross profit was primarily due to the significant drop in the unit sales revenue.

Selling expenses were decreased by $463 or 100% from $463 for the Comparable Quarter to $Nil in Q3. In terms of percentage of revenue, the rates were 0% in Q3 compared to 5.0% in the Comparable Quarter. There were no selling expenses because no sales occurred.

General and administrative expenses were increased by $33,714, or 40.1% from $84,054 for the Comparable Quarter to $117,768 for Q3. The increase is primarily due to the increment in salary and professional fee in Q3.

The following is a summary of general and administrative expenses for the three months ended September 30, 2021, and 2020.

	Sept 30, 2021		Sept 30, 2020		Difference
	Unaudited		Unaudited
Consulting fees	$	6,808	$	6,311	$	497
Salary and payroll expenses		43,926		23,140		20,786
Professional fees		14,350		6,240		8,110
Travel and entertainment		2,997		5,886		(2,889	)
Depreciation and amortization		42,213		39,859		2,354
Other		7,474		2,618		4,856
	$	117,768	$	84,054	$	33,714

Consulting fees were increased by $497, or 7.9%, from $6,311 in Comparable Quarter to $6,808 in Q3.

Our salary and payroll expenses were increased by $20,786 or 89.8%, to $43,926 in Q3, as compared to $23,140 in the Comparable Quarter. We anticipate that salary and wages on payroll expenses will rise in future periods as it becomes necessary to increase our staff in order to enhance our management quality for the listing requirement and to increase our production activities.

Professional fees were increased by $8,110, from $6,240 in Comparable Quarter to $14,350 in Q3. The increase of professional fees was due to the engagement of more independent professionals such as international lawyers.

Travel and entertainment expenses were decreased by $2,889, or 49.1%, from $5,886 in Comparable Quarter to $2,997 in Q3. The decrease of travel and entertainment expenses was due to the reduction of project-based travelling activities.

Depreciation and amortization expenses were increased by $2,354, or 5.9%, from $39,859 in Comparable Quarter to $42,213 in Q3.

Other expenses include items such as office expenses, software related costs, telephone and a variety of other miscellaneous expenses. None of these expenses alone changed significantly except property tax and land use tax, as the difference was $4,856, or 185.5% increase from $2,618 in Comparable Quarter to $7,474 in Q3.

Table of Contents

We anticipate that we will incur higher general and administrative expenses as a public company. We expect that our professional fees, cost of transfer agent, investor relations costs and other stock related costs will accordingly increase.

We also anticipate that selling, general and administrative expenses will concurrently increase with our increased activity in the future but will not increase in the same proportion to that of revenue.

Our loss from operations was increased by $35,063 or 42.4%, to negative $117,768 in Q3, from negative $82,705 in Comparable Quarter.

Non-operating expenses was decreased by $842, or 31.6%, to $1,823 in Q3, from $2,665 in Comparable Quarter.

The net loss attributed to the Company was increased by $34,221, or 40.1% to negative $119,591 in Q3, as compared to negative $85,370 in Comparable Quarter.

Result of Operations for the Nine months ended September 30, 2021 and 2020

Revenue was increased by $68,567, or 90.1% from $76,122, in the nine months ended September 30, 2020 (the “Nine-Month Comparable Period”) to $144,689 in the nine months ended September 30, 2021 (the “Nine Month of FY2021”). The increase in revenue during the Nine Month of FY2021 as compared to the Nine Month-Comparable Period was due to the unit sale price was increasing and became much more expensive in the Nine Month of FY2021.

Cost of sales was decreased by $10,508, or 12.4% from $84,472 in the Nine Month-Comparable Period to $73,964 in the Nine Month of FY2021. The decrease mainly was due to the decrease in sales volumes which were 407 tonnes in the Nine Month-Comparable Period decreased to 291 tonnes in the Nine Month of FY2021 while the unit cost increased from around $207 to $254 per tonnes. In terms of percentage of revenue, cost of sales was 51.1% in the Nine Month of FY2021 as compared to 111.0% in the Nine Month-Comparable Period.

Gross profit was increased by $79,075, or 947.0% from negative $8,350 in the Nine Month-Comparable Period to $70,725 in the Nine Month of FY2021. In terms of percentage of revenue, the gross profit percentage was increased by 48.9% for the Nine Month of FY2021 as compared to negative 11.0% for the Nine Month-Comparable Period. The increase of gross profit was primarily due to the significant rise in the unit sales price.

Selling expenses were increased by $56,521, or 2497.6%, to $58,784 in the Nine Month of FY2021 from $2,263 in the Nine Month-Comparable Period. In terms of percentage of revenue, the rates were 40.6% in the Nine Month of FY2021 compared to 3.0% in the Nine Month-Comparable Period. The increase is primarily due to the increase of sales commission expenses to stimulate the sale activities.

General and administrative expenses were increased by $108,576, or 42.0% to $367,269 in the Nine Month of FY2021 from $258,693 in the Nine Month-Comparable Period. The increase is primarily due to the increase of salary and payroll expenses and professional fees from $82,334 in the Nine Month-Comparable Period to $180,674 in the Nine Month of FY2021.

The following is a summary of general and administrative expenses for the nine months ended September 30, 2021, and 2020.

	Sept 30, 2021		Sept 30, 2020		Difference
	Unaudited		Unaudited
Consulting fees	$	16,062	$	13,887	$	2,175
Salary and payroll expenses		123,222		57,467		65,755
Professional fees		57,452		24,867		32,585
Travel and entertainment		8,683		15,906		(7,223	)
Depreciation and amortization		126,678		118,260		8,418
Other		35,172		28,306		6,866
	$	367,269	$	258,693	$	108,576

Consulting fees were increased by $2,175, or 15.7%, from $13,887 in the Nine Month-Comparable Period to $16,062 in the Nine Month of FY2021.

Our salary and payroll expenses were increased by $65,755 or 114.4%, to $123,222 in the Nine Month of FY2021, as compared to $57,467 in the Nine Month-Comparable Period. We anticipate that salary and wages on payroll expenses will rise in future periods as it becomes necessary to increase our staff in order to enhance our management quality for the listing requirement and to increase our production activities.

Professional fees were increased by $32,585, from $24,867 in the Nine Month-Comparable Period to $57,452 in the Nine Month of FY2021. The increase of professional fees was due to the engagement of more independent professionals such as international lawyers.

Table of Contents

Travel and entertainment expenses were decreased by $7,223, or 45.4%, from $15,906 in the Nine Month-Comparable Period to $8,683 in the Nine Month of FY2021. The decrease of travel and entertainment expenses was due to the reduction of business reception cost.

Depreciation and amortization expenses were increased by $8,418, or 7.1%, from $118,260 in the Nine Month-Comparable Period to $126,678 in the Nine Month of FY2021.

Other expenses include items such as office expenses, software related costs, telephone and a variety of other miscellaneous expenses. None of these expenses alone changed significantly except property tax and land use tax, as the difference was $6,866, or 24.3% increase from $28,306 in the Nine Month-Comparable Period to $35,172 in the Nine Month of FY2021.

Our loss from operations was increased by $86,022 or 31.9%, to negative $355,328 in the Nine Month of FY2021, from negative $269,306 in the Nine Month-Comparable Period.

Non-operating income (expenses) was decreased by $126,413, or 96.9%, to income of $4,015 in the Nine Month of FY2021, from income of $130,428 in the Nine Month-Comparable Period, of which mainly due to the decrease of other income by $155,734 from $163,201 in the Nine Month-Comparable Period to $7,467 in the Nine Month of FY2021.

The net loss attributed to the Company was increased by $208,870, or 146.6% to negative $351,313 in the Nine Month of FY2021, as compared to negative $142,443 in the Nine Month-Comparable Period.

Liquidity and Capital Resources

The Company’s liquidity and capital is dependent on whether the Company is capable of generating its revenues and increasing its capital for the development and expansion of its business.

Management plans to support the Company’s operation and its business strategy by raising funds through public and private offerings and relying on officers and directors to perform essential management functions with minimal compensation. If we do not raise all of the money we need from a public offering, we will have to find alternative sources, such as a private placement of securities, or loans from our officers, directors or others. The loans are likely to be unsecured, non-interest bearing and repayable at demand.

Moreover, management has actively taken steps to revise its operating and financial needs. Management believes that the Company’s current and available capital resources will allow it to continue its operations throughout this fiscal year.

Working capital

At September 30, 2021, we had a working capital deficit of $10,651,191, as compared to a working capital deficit of $10,399,991 at December 31, 2020. Of the working capital deficit at September 30, 2021, $10,144,177 was amount due to related parties and shareholder. Excluding the amounts due to related parties and shareholder, we would have had a negative working capital of $507,014 at September 30, 2021. As comparison, for the working capital deficit at December 31, 2020, $9,873,574 was amount due to related parties and holding. Excluding the amounts due to related parties and holding company, we would have had a negative working capital of $526,417 at December 31, 2020. The amounts due to related parties and shareholder are unsecured, interest free and repayable on demand.

Table of Contents

Operating activities

During the nine months ended September 30, 2021, operating activities used cash in operations of $192,106, and for the comparable year ended September 30, 2020, operating activities used cash in operations of $51,194. The use of cash in operating activities for the nine months ended September 30, 2021 was mainly derived from a net loss of $351,313 with non-cash items of $126,675 ($108,017 plus $18,658) in depreciation and amortization, negative $95,030 in inventory provision reversal; moreover, there was an increased in cash of $92,340 in inventory; an increase in cash of $47,836 in amount due to related parties; an increase in cash of $4,999 in other payables and an increase in cash of $5,931 in other tax payables, which were offset by a decrease in cash of $25,031 in accrued expenses. As comparison, the use of cash in operating activities for the nine months ended September 30, 2020 was mainly derived from a net loss of $138,878 with a non-cash item of $114,053 ($96,792 plus $17,261) in depreciation and amortization; negative $87,915 in reversal inventory provision; negative $50,953 in disposal gain of property, plant and equipment, moreover, there was an increase of $80,558 in inventories; an increase of $10,293 in account receivable; an increase of $78,284 in amount due to related parties.

Investing Activities

During the nine months ended September 30, 2021, investing activities provided $Nil of cash; and for comparable nine months ended September 30, 2020, investing activities provided $55,653 of cash in proceeds from sale of property, plant and equipment.

Financing Activities:

During the nine months ended September 30, 2021, financing activities provided cash of $198,698; and for comparable nine months ended September 30, 2020 financing activities used cash of $7,612. The change of cash provided by financing activities was derived from the changes in the amounts due to our shareholder.

As at September 30, 2021, net cash and cash equivalents balance was $33,253 as compared to balance $26,734 as at December 31, 2020.

As at September 30, 2021, stockholder’s equity was negative $7,755,762, compared to a negative equity of $7,414,541 at December 31, 2020.

The source of fund for supporting the Company’s business operation was loans from directors and shareholders. In the event the directors and shareholders do not continue to support the Company’s business operation, the Company could be short of funds and may not be able to operate any longer. The amounts due to related parties and director are interest-free loans. These loans are unsecured and have no fixed repayment terms.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds, loans from third parties, other debt facilities, or further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business.

Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to fund our operations over the next three months. We have no lines of credit or other bank financing arrangements. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a growing business; and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to the shareholdings of our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations. We will have to raise additional funds in the next twelve months in order to sustain and expand our operations. We currently do not have a specific plan of how we will obtain such funding; however, we anticipate that additional funding will be in the form of equity financing from the sale of our common stock. We have and will continue to seek to obtain short-term loans from our directors, although no future arrangement for additional loans has been made. We do not have any agreements with our directors concerning these loans. We do not have any arrangements in place for any future equity financing.

Since 2017, local government of Jinzhong City, Shanxi Province, China (where Shanxi Lutu and our production plant is located) has promulgated a new set of environmental regulations restricting the use of coal-fired boilers in factories. Since coal-powered generators were used in our production plant, our production activities starting from 2017 were restricted to a certain extent.

We cannot ensure that we can comply with the new environmental regulations in time. If that is the case, our production and our production capacity may be reduced as a result. This will affect our ability to generate income and to meet the demand of our customers, which in turn could have a material adverse effect on our financial condition and results of operations.

Table of Contents

Due to the enforcement on new environmental regulations over industrial production by coal-fired boilers by local authorities in Shanxi, the Company’s production was restricted to a certain extent in 2017. In order to fully comply with the new environmental regulations in place, management of the Company had planned to carry our rectification work and expected that the rectification work could be completed by mid of 2018 and full-scale production might resume in the second half of 2018. However, due to the shortage of funding to carry out the rectification work on our coal-powered generators, our production activities were restricted since second quarter in 2018. Our production and our production capacity was reduced as a result, significantly affected our ability to generate income and to meet the demand of our customers, which in turn had a material adverse effect on our financial condition and results of operations. The management had decided to maintain our business by way of sub-contracting or assignment of the production. Furthermore, the management had further researched for other business opportunity to utilize the reduced capacity of the property and equipment, in order to make better the worsened revenue.

Off-Balance Sheet Arrangements

As of the date of this Quarterly Report, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Going Concern

The independent auditors' report accompanying our December 31, 2020 audited financial statements filed in Form 10-K on September 21, 2021 contained an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. The financial statements have been prepared "assuming that we will continue as a going concern," which contemplates that we will realize our assets and satisfy our liabilities and commitments in the ordinary course of business.

COVID-19

ITEM 3: QUANTITATIVE AND QUALITAIVE DISCLOSURE ABOUT MARKET RISK

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 4. CONTROLS AND PROCEDURES

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted by an officer under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2021. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the nine months period ended September 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Civil case with Mr. Yao Gui Mu

Table of Contents

Criminal investigation regarding a potential fraud with one of its former customers

Criminal investigation against one of GVBT’s former employee

The Company disagreed with the decision and appeal to the People’s Procuratorate of Jin Zhong City, Yu Ci District on May 7, 2021, and the appeal was accepted on July 5, 2021.

Table of Contents

ITEM 1A. RISK FACTORS

Not applicable to a smaller reporting company.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

No report required.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

No report required.

ITEM 4. MINESAFETY DISCLOUSURES

Not applicable.

ITEM 5. OTHER INFORMATION

No report required.

Table of Contents

ITEM 6. EXHIBITS

Exhibits

Exhibit No.		Description

31.1		Certification of CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1		Certification of CEO and CFO Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Table of Contents

SIGNATURE

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GREEN VISION BIOTECHNOLOGY CORP.

Date: November 10, 2021	By :	/s/ William Ching Wan Lam
		William Ching Wan Lam
		Chief Executive Officer

Date: November 10, 2021	By :	/s/ Kwok Leung Lo
		Kwok Leung Lo
		Chief Financial Officer

GREEN VISION BIOTECHNOLOGY CORP. 10-Q